Intravesical therapy for lower urinary tract symptoms

Urological Science

Volumn 23, Issue 3, 2012, Pages 70-77

  Nirmal, Jayabalan ^a   Chuang, Yao Chi ^b   Tyagi, Pradeep ^a   Chancellor, Michael B ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Cystitis; Intravesical therapy; Overactive bladder

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; BOTULINUM TOXIN A; CAPSAICIN; CHONDROITIN SULFATE; CISPLATIN; DARIFENACIN; DENDRIMER; DIMETHYL SULFOXIDE; DOXORUBICIN; EPIRUBICIN; HEPARIN; HYALURONIC ACID; LIDOCAINE; LIPOSOME; MAGNETIC NANOPARTICLE; MITOMYCIN; MUSCARINIC RECEPTOR BLOCKING AGENT; NANOPARTICLE; OXYBUTYNIN; PIRARUBICIN; PLACEBO; POLY(ETHYL 2 CYANOACRYLATE); POTASSIUM CHANNEL; PROENKEPHALIN; RESINIFERATOXIN; SILVER NANOPARTICLE; SOLIFENACIN; TACROLIMUS; TANEZUMAB; UNINDEXED DRUG;

BLADDER CANCER; DISEASE MODEL; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG MECHANISM; DRUG TRANSPORT; ELECTROMOTIVE DRUG ADMINISTRATION; HUMAN; HYDROGEL; INTERSTITIAL CYSTITIS; INTRAVESICAL DRUG ADMINISTRATION; LOWER URINARY TRACT SYMPTOM; MICTURITION; NEUROGENIC BLADDER; NONHUMAN; OVERACTIVE BLADDER; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR BLOCKING; REVIEW; UNSPECIFIED SIDE EFFECT; URINE INCONTINENCE; VIRAL GENE DELIVERY SYSTEM;

EID: 84867403772     PISSN: 18795226     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urols.2012.07.005     Document Type: Review

References (88)

1. Shen Z., Shen T., Wientjes M.G., O'Donnell M.A., Au J.L. Intravesical treatments of bladder cancer: review. Pharm Res 2008, 25:1500-1510.
2. Highley M.S., van Oosterom A.T., Maes R.A., De Bruijn E.A. Intravesical drug delivery. Pharmacokinetic and clinical considerations. Clin Pharmacokinet 1999, 37:59-73.
3. Melicow M.M. The urothelium: a battleground for oncogenesis. J Urol 1978, 120:43-47.
4. Apodaca G. The uroepithelium: not just a passive barrier. Traffic 2004, 5:117-128.
5. Lu Z., Yeh T.K., Tsai M., Au J.L., Wientjes M.G. Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy. Clin Cancer Res 2004, 10:7677-7684.
6. Parsons J.K., Parsons C.L. The historical origins of interstitial cystitis. J Urol 2004, 171:20-22.
7. Parsons C.L., Greene R.A., Chung M., Stanford E.J., Singh G. Abnormal urinary potassium metabolism in patients with interstitial cystitis. J Urol 2005, 173:1182-1185.
8. Theoharides T.C., Sant G.R. A pilot open label study of cystoprotek in interstitial cystitis. Int J Immunopathol Pharmacol 2005, 18:183-188.
9. Smaldone M.C., Vodovotz Y., Tyagi V., Barclay D., Philips B.J., Yoshimura N., et al. Multiplex analysis of urinary cytokine levels in rat model of cyclophosphamide-induced cystitis. Urology 2009, 73:421-426.
10. Abrams P., Cardozo L., Fall M., Griffiths D., Rosier P., Ulmsten U., et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002, 21:167-178.
11. de Groat W.C. A neurologic basis for the overactive bladder. Urology 1997, 50(6A Suppl.):36-52. discussion 53-6.
12. Brading A.F., Turner W.H. The unstable bladder: towards a common mechanism. Br J Urol 1994, 73:3-8.
13. Drake M.J., Mills I.W., Gillespie J.I. Model of peripheral autonomous modules and a myovesical plexus in normal and overactive bladder function. Lancet 2001, 358:401-403.
14. Andersson K.E. Detrusor myocyte activity and afferent signaling. Neurourol Urodyn 2010, 29:97-106.
15. Chuang Y.C., Thomas C.A., Tyagi S., Yoshimura N., Tyagi P., Chancellor M.B. Human urine with solifenacin intake but not tolterodine or darifenacin intake blocks detrusor overactivity. Int Urogynecol J Pelvic Floor Dysfunct 2008, 19:1353-1357.
16. Henderson E., Drake M. Overactive bladder. Maturitas 2010, 66:257-262.
17. Kaufman J., Tyagi V., Anthony M., Chancellor M.B., Tyagi P. State of the art in intravesical therapy for lower urinary tract symptoms. Rev Urol 2010, 12:e181-e189.
18. GuhaSarkar S., Banerjee R. Intravesical drug delivery: challenges, current status, opportunities and novel strategies. J Control Release 2010, 148:147-159.
19. Gao X., Au J.L., Badalament R.A., Wientjes M.G. Bladder tissue uptake of mitomycin C during intravesical therapy is linear with drug concentration in urine. Clin Cancer Res 1998, 4:139-143.
20. Au J.L., Badalament R.A., Wientjes M.G., Young D.C., Warner J.A., Venema P.L., et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 2001, 93:597-604.
21. Au J.L., Jang S.H., Wientjes M.G. Clinical aspects of drug delivery to tumors. J Control Release 2002, 78:81-95.
22. Song D., Wientjes M.G., Au J.L. Bladder tissue pharmacokinetics of intravesical taxol. Cancer Chemother Pharmacol 1997, 40:285-292.
23. Parsons C.L., Boychuk D., Jones S., Hurst R., Callahan H. Bladder surface glycosaminoglycans: an epithelial permeability barrier. J Urol 1990, 143:139-142.
24. + transport by rabbit urinary bladder, a tight epithelium. J Membr Biol 1976, 28:1-40.
25. Negrete H.O., Lavelle J.P., Berg J., Lewis S.A., Zeidel M.L. Permeability properties of the intact mammalian bladder epithelium. Am J Physiol 1996, 271:F886-F894.
26. Khandelwal P., Abraham S.N., Apodaca G. Cell biology and physiology of the uroepithelium. Am J Physiol Renal Physiol 2009, 297:F1477-F1501.
27. Min G., Zhou G., Schapira M., Sun T.T., Kong X.P. Structural basis of urothelial permeability barrier function as revealed by Cryo-EM studies of the 16 nm uroplakin particle. J Cell Sci 2003, 116:4087-4094.
28. Tammela T., Wein A.J., Monson F.C., Levin R.M. Urothelial permeability of the isolated whole bladder. Neurourol Urodyn 1993, 12:39-47.
29. Daha L.K., Riedl C.R., Lazar D., Hohlbrugger G., Pflüger H. Do cystometric findings predict the results of intravesical hyaluronic acid in women with interstitial cystitis?. Eur Urol 2005, 47:393-397.
30. Parsons C.L. Current strategies for managing interstitial cystitis. Expert Opin Pharmacother 2004, 5:287-293.
31. Parsons C.L., Housley T., Schmidt J.D., Lebow D. Treatment of interstitial cystitis with intravesical heparin. Br J Urol 1994, 73:504-507.
32. Shao Y., Shen Z.J., Rui W.B., Zhou W.L. Intravesical instillation of hyaluronic acid prolonged the effect of bladder hydrodistention in patients with severe interstitial cystitis. Urology 2010, 75:547-550.
33. Hauser P.J., Buethe D.A., Califano J., Sofinowski T.M., Culkin D.J., Hurst R.E. Restoring barrier function to acid damaged bladder by intravesical chondroitin sulfate. J Urol 2009, 182:2477-2482.
34. Parkin J., Shea C., Sant G.R. Intravesical dimethyl sulfoxide (DMSO) for interstitial cystitis-a practical approach. Urology 1997, 49:105-107.
35. Sant G.R. Intravesical 50% dimethyl sulfoxide (RIMSO-50) in treatment of interstitial cystitis. Urology 1987, 29:17-21.
36. Fowler J.E. Prospective study of intravesical dimethyl sulfoxide in treatment of suspected early interstitial cystitis. Urology 1981, 18:21-26.
37. Barker S.B., Matthews P.N., Philip P.F., Williams G. Prospective study of intravesical dimethyl sulphoxide in the treatment of chronic inflammatory bladder disease. Br J Urol 1987, 59:142-144.
38. Perez-Marrero R., Emerson L.E., Feltis J.T. A controlled study of dimethyl sulfoxide in interstitial cystitis. J Urol 1988, 140:36-39.
39. Sun Y., Chai T.C. Effects of dimethyl sulphoxide and heparin on stretch-activated ATP release by bladder urothelial cells from patients with interstitial cystitis. BJU Int 2002, 90:381-385.
40. Giannantoni A., Di Stasi S.M., Chancellor M.B., Costantini E., Porena M. New frontiers in intravesical therapies and drug delivery. Eur Urol 2006, 50:1183-1193.
41. Parsons C.L. Successful downregulation of bladder sensory nerves with combination of heparin and alkalinized lidocaine in patients with interstitial cystitis. Urology 2005, 65:45-48.
42. Chancellor M.B., de Groat W.C. Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder. J Urol 1999, 162:3-11.
43. Byrne D.S., Das A., Sedor J., Huang B., Rivas D.A., Flood H.J., et al. Effect of intravesical capsaicin and vehicle on bladder integrity control and spinal cord injured rats. J Urol 1998, 159:1074-1078.
44. Lazzeri M., Beneforti P., Spinelli M., Zanollo A., Barbagli G., Turini D. Intravesical resiniferatoxin for the treatment of hypersensitive disorder: a randomized placebo controlled study. J Urol 2000, 164:676-679.
45. Van Meel T.D., De Wachter S., Wyndaele J.J. The effect of intravesical oxybutynin on the ice water test and on electrical perception thresholds in patients with neurogenic detrusor overactivity. Neurourol Urodyn 2010, 29:391-394.
46. Hayashi A., Saito M., Okada S., Hanada T., Watanabe T., Satoh K., et al. Treatment with modified intravesical oxybutynin chloride for neurogenic bladder in children. J Pediatr Urol 2007, 3:438-442.
47. Buyse G., Waldeck K., Verpoorten C., Björk H., Casaer P., Andersson K.E. Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. J Urol 1998, 160:892-896.
48. Abramov Y., Sand P.K. Oxybutynin for treatment of urge urinary incontinence and overactive bladder: an updated review. Expert Opin Pharmacother 2004, 5:2351-2359.
49. Vemulakonda V.M., Somogyi G.T., Kiss S., Salas N.A., Boone T.B., Smith C.P. Inhibitory effect of intravesically applied botulinum toxin A in chronic bladder inflammation. J Urol 2005, 173:621-624.
50. Khera M., Somogyi G.T., Salas N.A., Kiss S., Boone T.B., Smith C.P. In vivo effects of botulinum toxin A on visceral sensory function in chronic spinal cord-injured rats. Urology 2005, 66:208-212.
51. Tzan C.J., Berg J.R., Lewis S.A. Mammalian urinary bladder permeability is altered by cationic proteins: modulation by divalent cations. Am J Physiol 1994, 267:C1013-C1026.
52. Tyagi P., Banerjee R., Basu S., Yoshimura N., Chancellor M., Huang L. Intravesical antisense therapy for cystitis using TAT-peptide nucleic acid conjugates. Mol Pharm 2006, 3:398-406.
53. Yoshimura N., Bennett N.E., Hayashi Y., Ogawa T., Nishizawa O., Chancellor M.B., et al. Bladder overactivity and hyperexcitability of bladder afferent neurons after intrathecal delivery of nerve growth factor in rats. J Neurosci 2006, 26:10847-10855.
54. Seki S., Sasaki K., Igawa Y., Nishizawa O., Chancellor M.B., De Groat W.C., et al. Suppression of detrusor-sphincter dyssynergia by immunoneutralization of nerve growth factor in lumbosacral spinal cord in spinal cord injured rats. J Urol 2004, 171:478-482.
55. Evans R.J., Moldwin R.M., Cossons N., Darekar A., Mills I.W., Scholfield D. Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis. J Urol 2011, 185:1716-1721.
56. Tyagi V., Sugino Y., Yoshimura N., Chancellor M., Tyagi P., Oak R. Liposomes assisted bladder uptake of NGF antisense oligonucleotides ameliorate symptoms of detrusor overactivity in rat model. J Urol 2011, 185(Suppl 4):e318.
57. Glazer E.J., Basbaum A.I. Leucine enkephalin: localization in and axoplasmic transport by sacral parasympathetic preganglionic neurons. Science 1980, 208:1479-1481.
58. de Groat W.C. Neuropeptides in pelvic afferent pathways. Experientia 1987, 43:801-813.
59. Yokoyama H., Sasaki K., Franks M.E., Goins W.F., Goss J.R., de Groat W.C., et al. Gene therapy for bladder overactivity and nociception with herpes simplex virus vectors expressing preproenkephalin. Hum Gene Ther 2009, 20:63-71.
60. Christ G.J., Day N.S., Day M., Santizo C., Zhao W., Sclafani T., et al. Bladder injection of " naked" hSlo/pcDNA3 ameliorates detrusor hyperactivity in obstructed rats in vivo. Am J Physiol Regul Integr Comp Physiol 2001, 281:R1699-R1709.
61. Cortesi R., Nastruzzi C. Liposomes, micelles and microemulsions as new delivery systems for cytotoxic alkaloids. Pharm Sci Technol Today 1999, 2:288-298.
62. Fraser M.O., Chuang Y.C., Tyagi P., Yokoyama T., Yoshimura N., Huang L., et al. Intravesical liposome administration-a novel treatment for hyperactive bladder in the rat. Urology 2003, 61:656-663.
63. Chuang Y.C., Lee W.C., Lee W.C., Chiang P.H. Intravesical liposome versus oral pentosan polysulfate for interstitial cystitis/painful bladder syndrome. J Urol 2009, 182:1393-1400.
64. Chuang Y.C., Tyagi P., Huang H.Y., Yoshimura N., Wu M., Kaufman J., et al. Intravesical immune suppression by liposomal tacrolimus in cyclophosphamide-induced inflammatory cystitis. Neurourol Urodyn 2011, 30:421-427.
65. Tyagi P., Chancellor M.B., Li Z., De Groat W.C., Yoshimura N., Fraser M.O., et al. Urodynamic and immunohistochemical evaluation of intravesical capsaicin delivery using thermosensitive hydrogel and liposomes. J Urol 2004, 171:483-489.
66. Chuang Y.C., Tyagi P., Huang C.C., Yoshimura N., Wu M., Kaufman J., et al. Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin a delivery using liposomes. J Urol 2009, 182:786-792.
67. Caccin P., Rossetto O., Rigoni M., Johnson E., Schiavo G., Montecucco C. VAMP/synaptobrevin cleavage by tetanus and botulinum neurotoxins is strongly enhanced by acidic liposomes. FEBS Lett 2003, 542:132-136.
68. Alexis F., Rhee J.W., Richie J.P., Radovic-Moreno A.F., Langer R., Farokhzad O.C. New frontiers in nanotechnology for cancer treatment. Urol Oncol 2008, 26:74-85.
69. Chang L.C., Wu S.C., Tsai J.W., Yu T.J., Tsai T.R. Optimization of epirubicin nanoparticles using experimental design for enhanced intravesical drug delivery. Int J Pharm 2009, 376:195-203.
70. Kumari A., Yadav S.K., Yadav S.C. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 2010, 75:1-18.
71. Gommersall L., Shergill I.S., Ahmed H.U., Hayne D., Arya M., Patel H.R., et al. Nanotechnology and its relevance to the urologist. Eur Urol 2007, 52:368-375.
72. Arruebo M., Fernández-Pacheco R., Ibarra M.R., Santamaría J. Magnetic nanoparticles for drug delivery. Nano Today 2007, 2:22-32.
73. Chertok B., Moffat B.A., David A.E., Yu F., Bergemann C., Ross B.D., et al. Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials 2008, 29:487-496.
74. Leakakos T., Ji C., Lawson G., Peterson C., Goodwin S. Intravesical administration of doxorubicin to swine bladder using magnetically targeted carriers. Cancer Chemother Pharmacol 2003, 51:445-450.
75. Duncan R., Izzo L. Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev 2005, 57:2215-2237.
76. Svenson S. Dendrimers as versatile platform in drug delivery applications. Eur J Pharm Biopharm 2009, 71:445-462.
77. Esfand R., Tomalia D.A. Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov Today 2001, 6:427-436.
78. Tang M.X., Redemann C.T., Szoka F.C. In vitro gene delivery by degraded polyamidoamine dendrimers. Bioconjug Chem 1996, 7:703-714.
79. Patri A.K., Myc A., Beals J., Thomas T.P., Bander N.H., Baker J.R. Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjug Chem 2004, 15:1174-1181.
80. François A, Matthieu Y, Bezdetnaya L, Guillemin F, Battah S, Macrobert A et al. Improvement of fluorescence diagnosis of bladder cancer with ALA dendrimers. In: 14th Congress of the European Society for Photobiology (ESP 2011), Sept 1-6, 2011; Geneva, Switzerland.
81. Boucher W., Stern J.M., Kotsinyan V., Kempuraj D., Papaliodis D., Cohen M.S., et al. Intravesical nanocrystalline silver decreases experimental bladder inflammation. J Urol 2008, 179:1598-1602.
82. Tyagi P., Li Z., Chancellor M., De Groat W.C., Yoshimura N., Huang L. Sustained intravesical drug delivery using thermo hydrogel. Pharm Res 2004, 21:832-837.
83. Smart J.D. The basics and underlying mechanisms of mucoadhesion. Adv Drug Deliv Rev 2005, 57:1556-1568.
84. Tyagi P., Wu P.C., Chancellor M., Yoshimura N., Huang L. Recent advances in intravesical drug/gene delivery. Mol Pharm 2006, 3:369-379.
85. Eroĝlu M., Irmak S., Acar A., Denkbaş E.B. Design and evaluation of a mucoadhesive therapeutic agent delivery system for postoperative chemotherapy in superficial bladder cancer. Int J Pharm 2002, 235:51-59.
86. Jordan J.L., Henderson S., Elson C.M., Zhou J., Kydonieus A., Downie J., et al. Use of a sulfated chitosan derivative to reduce bladder inflammation in the rat. Urology 2007, 70:1014-1018.
87. Barthelmes J., Perera G., Hombach J., Dunnhaupt S., Bernkop-Schnürch A. Development of a mucoadhesive nanoparticulate drug delivery system for a targeted drug release in the bladder. Int J Pharm 2011, 416:339-345.
88. Bach P., Wormland R.T., Möhring C., Goepel M. Electromotive drug-administration: a pilot study for minimal-invasive treatment of therapy-resistant idiopathic detrusor overactivity. Neurourol Urodyn 2009, 28:209-213.